加载中
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
前收盘价
US$3.51
−US$0.12 · -3.31%
盘中时间采用ET。市场数据可能有所延迟。
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
日内区间
当前US$3.51
52周区间
当前US$3.51
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
48
合理估值
情绪
43
多空交织
风险
96
极高风险
动量
24
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
日内区间
当前US$3.51
52周区间
当前US$3.51
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 研究与开发 | 223.7万 USD | 33.5万 USD | 56.7万 USD | 111.6万 USD |
| 销售、一般及管理费用 | 266.7万 USD | 74.3万 USD | 58万 USD | 92.6万 USD |
| 营业费用 | 490.4万 USD | 107.8万 USD | 114.7万 USD | 204.2万 USD |
| 利息支出 | — | 2.9万 USD | 4.9万 USD | 1.8万 USD |
| 营业利润 | −490.4万 USD | −107.8万 USD | −114.7万 USD | −204.2万 USD |
| 净利润 | −585.6万 USD | −153.2万 USD | −105.1万 USD | −171.1万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.00
上涨空间 526.78%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
